Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Description:

“Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability”, which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019.

The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan.

The report includes:

- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
- Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
- Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
- In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
- Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

The report will enhance your decision-making capability by allowing you to:

- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers
in the anti-epileptic drugs market

- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Contents:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Co-morbidities/Complications
2.7 Diagnosis
2.8 Prognosis
2.9 Treatment Efficacy
2.10 Treatment Options
  2.10.1 Ion Channel Modulators
  2.10.2 GABA-ergic Facilitation
  2.10.3 Excitatory Amino Acid Inhibitors
  2.10.4 Synaptic Modulators
  2.11 Non-pharmacological Management
    2.11.1 Lobectomy and Lesionectomy
    2.11.2 Ketogenic Diet and Modified Atkins Diet
    2.11.3 Vagus Nerve Stimulation

3 Epilepsy Therapeutic Landscape
3.1 Overview
3.2 Lyrica (pregabalin)
3.3 Lamictal (lamotrigine)
3.4 Keppra (levetiracetam)
3.5 Zonegran (zonisamide)
3.6 Vimpat (lacosamide)
3.7 Aptiom/Zebinix (eslicarbazepine acetate)
3.8 Fycompa (perampanel)
3.9 Trobalt/Potiga (ezogabine/retigabine)
3.10 Banzel/Inovelon (rufinamide)
3.11 Comparative Efficacy and Safety of Marketed Products

4 Pipeline for Epilepsy Therapeutics
4.1 Overall Pipeline
4.2 Pipeline by Mechanism of Action
4.3 Clinical Trials
  4.3.1 Failure Rate
  4.3.2 Patient Enrolment and Clinical Trial Size
  4.3.3 Clinical Trial Duration
4.4 Promising Pipeline Candidates
  4.4.1 Brivaracetam – UCB
  4.4.2 Ganaxolone – Marinus Pharmaceuticals

5 Epilepsy Therapeutics Market Forecast to 2019
5.1 Geographical Markets
  5.1.1 Key Asia-Pacific Markets
  5.1.2 China
  5.1.3 India
  5.1.4 Japan
  5.1.5 Australia
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Research and Development Co-development Agreements
6.3 Research and Development Licensing Agreements

7 Appendix
7.1 Abbreviations
7.2 References
7.3 References for Heat Maps
7.4 Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 IND-filed and Phase
7.4.4 Phase I
7.4.5 Phase II
7.4.6 Phase III
7.4.7 Pre-registration
7.5 Market Forecasting Data Tables to 2019
7.5.1 Asia-Pacific
7.5.2 China
7.5.3 India
7.5.4 Japan
7.5.5 Australia
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013
Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012–2019
Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012–2019
Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012–2019
Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019
Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012–2019

1.2 List of Figures
Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012
Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013
Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013
Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013
Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013
Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013
Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013
Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013
Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013
Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012–2019
Figure 14: Epilepsy Therapeutics, China, Market Size, 2012–2019
Figure 15: Epilepsy Therapeutics, India, Market Size, 2012–2019
Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012–2019
Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012–2019
Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013
Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013
Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013
Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013
Figure 22: Research Market Forecasting Model

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/2775075/](http://www.researchandmarkets.com/reports/2775075/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
Web Address: http://www.researchandmarkets.com/reports/2775075/
Office Code: SCH3X2Z6

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: 
Last Name: 
Email Address: *
Job Title: 
Organisation: 
Address: 
City: 
Postal / Zip Code: 
Country: 
Phone Number: 
Fax Number: 

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World